Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonafarnib and Ritonavir with/without PEG IFN-alfa-2a in Hepatitis Delta (D-LIVR)
NCT03719313Phase 3Completed
- Sponsor
- Eiger BioPharmaceuticals, Inc.
- Start
- Dec 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of lonafarnib in hepatitis D (HDV) (4 arms), sponsored by Eiger BioPharmaceuticals, Inc. Primary endpoints: Composite virologic and biochemical response rate at EOT (LNF/RTV vs Placebo) at 48 weeks and Composite virologic and biochemical response rate at EOT (LNF/RTV + PEG IFN vs Placebo) at 48 weeks. Started Dec 2018; status: completed.
02
Drugs
lonafarnib
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT03719313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719313.